Drug therapy: Pharmacologic treatment of cancer pain

New England Journal of Medicine

Volumn 335, Issue 15, 1996, Pages 1124-1132

  Levy, Michael H ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTICONVULSIVE AGENT; BACLOFEN; CALCITONIN; CODEINE; CORTICOSTEROID; DEXTROPROPOXYPHENE; DIHYDROCODEINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; MEXILETINE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PAMIDRONIC ACID; PARACETAMOL; STRONTIUM 89; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ANALGESIA; BONE PAIN; CANCER ADJUVANT THERAPY; CANCER PAIN; CLINICAL TRIAL; CONSTIPATION; HEADACHE; HUMAN; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; SUBCUTANEOUS DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION; VERTIGO; DRUG ADMINISTRATION; DRUG COMBINATION; NEOPLASM; PAIN;

ANALGESICS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; NEOPLASMS; PAIN;

EID: 0030579008     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199610103351507     Document Type: Review

References (101)

1. Cancer facts & figures-1995. Atlanta: American Cancer Society, 1995.
2. Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in out-patients with metastatic cancer. N Engl J Med 1994;330:592-6.
3. Zhukovsky DS, Gorowski E, Hausdorff J, Napolitano B, Lesser M. Unmet analgesic needs in cancer patients. J Pain Symptom Manage 1995;10: 113-9.
4. Coyle N, Adelhardt J, Foley KM, Portenoy RK. Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. J Pain Symptom Manage 1990;5:83-93.
5. Portenoy RK, Miransky J, Thaler HT, et al. Pain in ambulatory patients with lung or colon cancer: prevalence, characteristics, and effect. Cancer 1992;70:1616-24.
6. Grond S, Zech D, Diefenbach C, Bischoff A. Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic. J Pain Symptom Manage 1994;9: 372-82.
7. Schug SA, Zech D, Dorr U. Cancer pain management according to WHO analgesic guidelines. J Pain Symptom Manage 1990;5:27-32.
8. Ventafridda V, Caraceni A, Gamba A. Field-testing of the WHO guidelines for cancer pain relief: summary report of demonstration projects. In: Foley KM, Bonica JJ, Ventafridda V, eds. Proceedings of the Second International Congress of Cancer Pain. Vol. 16 of Advances in pain research and therapy. New York: Raven Press, 1990:451-64.
9. Arbit E, ed. Management of cancer-related pain. Mount Kisco, N.Y.: Futura Publishing, 1993.
10. Patt RB, ed. Cancer pain. Philadelphia: J.B. Lippincott, 1993.
11. Rosen SM. Procedural control of cancer pain. Semin Oncol 1994;21: 740-7.
12. Bottomley DM, Hanks GW. Subcutaneous midazolam infusion in palliative care. J Pain Symptom Manage 1990;5:259-61.
13. Greene WR, Davis WH. Titrated intravenous barbiturates in control of symptoms in patients with terminal cancer. South Med J 1991;84:332-7.
14. Moyle J. The use of propofol in palliative medicine. J Pain Symptom Manage 1995;10:643-6.
15. Ferrer-Brechner T. The management of pain associated with malignancy. Semin Anesth 1985;4:313-22.
16. Levy MH. Integration of pain management into comprehensive cancer care. Cancer 1989;63:Suppl:2328-35.
17. Jacox A, Carr DB, Payne R, et al. Management of cancer pain: clinical practice guideline. No. 9. Rockville, Md.: Agency for Health Care Policy and Research, 1994. (AHCPR publication no. 94-0592.)
18. Cherny NI, Portenoy RK. The management of cancer pain. CA Cancer J Clin 1994;44:263-303.
19. Levy MH. Pharmacologic management of cancer pain. Semin Oncol 1994;21:718-39.
20. Principles of analgesic use in the treatment of acute pain and chronic cancer pain. 3rd ed. Skokie, III.: American Pain Society, 1992.
21. Doyle D, Hanks GWC, MacDonald N, eds Oxford textbook of palliative medicine. Oxford, England: Oxford University Press, 1993.
22. Twycross R. Pain relief in advanced cancer. London: Churchill Livingstone, 1994.
23. Cleeland CS. The impact of pain on the patient with cancer. Cancer 1984;54:Suppl:2635-41.
24. Fishman B, Pasternak S, Wallenstein SL, Houde RW, Holland JC, Foley KM. The Memorial Pain Assessment Card: a valid instrument for the evaluation of cancer pain. Cancer 1987;60:1151-8.
25. Au E, Loprinzi CL, Dhodapkar M, et al. Regular use of a verbal pain scale improves the understanding of oncology inpatient pain intensity. J Clin Oncol 1994;12:2751-5.
26. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995;61:277-84.
27. Cancer pain relief and palliative care: report of a WHO expert committee. WHO Tech Rep Ser 1990;804:1-73.
28. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 1994;272:1845-50.
29. Strom BL. Adverse reactions to over-the-counter analgesics taken for therapeutic purposes. JAMA 1994;272:1866-7.
30. Stuart MJ, Murphy S, Oski FA, Evans AE, Donaldson MH, Gardner FH. Platelet function in recipients of platelets from donors ingesting aspirin. N Engl J Med 1972;287:1105-9.
31. Stuart JJ, Pisko EJ. Choline magnesium trisalicylate does not impair platelet aggregation. Pharmatherapeutica 1981;2:547-51.
32. Johnson JR, Miller AJ. The efficacy of choline magnesium trisalicylate (CMT) in the management of metastatic bone pain: a pilot study. Palliat Med 1994;8:129-35.
33. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs - differences and similarities. N Engl J Med 1991;324:1716-25. [Erratum, N Engl J Med 1991;325:747]
34. Eisenberg E, Berkey CS, Carr DB, Mosteller F, Chalmers TC. Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a metaanalysis. J Clin Oncol 1994;12:2756-65.
35. Hollander D. Gastrointestinal complications of nonsteroidal antiinflammatory drugs: prophylactic and therapeutic strategies. Am J Med 1994;96:274-81.
36. Valentini M, Cannizzaro R, Poletti M, et al. Nonsteroidal antiinflammatory drugs for cancer pain: comparison between misoprostol and ranitidine in prevention of upper gastrointestinal damage. J Clin Oncol 1995; 13:2637-42.
37. Sunshine A. New clinical experience with tramadol. Drugs 1994;47: Suppl 1:8-18.
38. Wilder-Smith CH, Schimke J, Osterwalder B, Senn HJ. Oral tramadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain. Ann Oncol 1994;5:141-6.
39. Stubhaug A, Grimstad J, Breivik H. Lack of analgesic effect of 50 and 100 mg oral tramadol after orthopaedic surgery: a randomized, double-blind, placebo and standard active drug comparison. Pain 1995;62: 111-8.
40. Foley KM. Changing concepts of tolerance to opioids: what the cancer patient has taught us. In: Chapman CR, Foley KM, eds. Current and emerging issues in cancer pain: research and practice. New York: Raven Press, 1993:331-50.
41. Jaffe JH. Misinformation: euphoria and addiction. In: Hill CS Jr, Fields WS, eds. Drug treatment of cancer pain in a drug-oriented society. Vol. 11 of Advances in pain research and therapy. New York: Raven Press, 1989:163-74.
42. Desmeules J, Gascon M-P, Dayer P, Magistris M. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 1991;41:23-6.
43. Sindrup SH, Arendt-Nielsen L, Brosen K, et al. The effect of quinidine on the analgesic effect of codeine. Eur J Clin Pharmacol 1992;42:587-91.
44. Galer BS, Coyle N, Pasternak GW, Portenoy RK. Individual variability in the response to different opioids: report of five cases. Pain 1992;49:87-91.
45. MacDonald N, Der L, Allan S, Champion P. Opioid hyperexcitability: the application of alternate opioid therapy. Pain 1993;53:353-5.
46. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995; 10:378-84.
47. Thirlwell MP, Sloan PA, Maroun JA, et al. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. Cancer 1989;63:Suppl:2275-83.
48. Hanks GW. Controlled-release morphine (MST contin) in advanced cancer: the European experience. Cancer 1989;63:Suppl:2378-82.
49. Finn JW, Walsh TD, MacDonald N, Bruera E, Krebs LU, Shepard KV. Placebo-blinded study of morphine sulfate sustained-release tablets and immediate-release morphine sulfate solution in outpatients with chronic pain due to advanced cancer. J Clin Oncol 1993;11:967-72.
50. Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990;47:639-46.
51. Glare PA, Walsh TD. Dose-ranging study of oxycodone for chronic pain in advanced cancer. J Clin Oncol 1993;11:973-8.
52. Sunshine A, Olson NZ, Colon A, Rivera J, Fitzmartin R, Grandy R. Onset and duration of analgesia for controlled release vs. immediate release oxycodone alone or in combination with acetaminophen in postoperative pain. Clin Pharmacol Ther 1995;57:137. abstract.
53. Kaiko R, Lacouture P, Hopf K, Brown J, Goldenheim P. Analgesic onset and potency of oral controlled-release (CR) oxycodone and CR morphine. Clin Pharmacol Ther 1996;59:130. abstract.
54. Roy SD, Flynn GL. Solubility and related physicochemical properties of narcotic analgesics. Pharm Res 1988;5:580-6.
55. Hays H, Hagen N, Thirlwell M, et al. Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer pain. Cancer 1994;74:1808-16.
56. Payne R. Transdermal fentanyl: suggested recommendations for clinical use. J Pain Symptom Manage 1992;7:Suppl:S40-S44.
57. Hanks GW, Fallon MT. Transdermal fentanyl in cancer pain: conversion from oral morphine. J Pain Symptom Manage 1995;10:87.
58. Brescia FJ, Portenoy RK, Ryan M, Krasnoff L, Gray G. Pain, opioid use, and survival in hospitalized patients with advanced cancer. J Clin Oncol 1992;10:149-55.
59. Ferrell BR, Griffith H. Cost issues related to pain management: report from the Cancer Pain Panel of the Agency for Health Care Policy and Research. J Pain Symptom Manage 1994;9:221-34.
60. Fine PG, Marcus M, De Boer AJ, Van der Oord B. An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. Pain 1991;45:149-53.
61. De Conno F, Ripamonti C, Saita L, MacEachern T, Hanson J, Bruera E. Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. J Clin Oncol 1995;13:1004-8.
62. Kerr IG, Sone M, Deangelis C, Iscoe N, Mackenzie R, Schueller T. Continuous narcotic infusion with patient-controlled analgesia for chronic cancer pain in outpatients. Ann Intern Med 1988;108:554-7.
63. Payne R. Role of epidural and intrathecal narcotics and peptides in the management of cancer pain. Med Clin North Am 1987;71:313-27.
64. Du Pen SL, Williams AR. Management of patients receiving combined epidural morphine and bupivacaine for the treatment of cancer pain. J Pain Symptom Manage 1992;7:125-7.
65. Bedder MD, Burchiel K, Larson A. Cost analysis of two implantable narcotic delivery systems. J Pain Symptom Manage 1991;6:368-73.
66. Eisenach JC, DuPen S, Dubois M, Miguel R, Allin D. Epidural clonidine analgesia for intractable cancer pain. Pain 1995;61:391-9.
67. Cramond T, Stuart G. Intraventricular morphine for intractable pain of advanced cancer J Pain Symptom Manage 1993;8:465-73.
68. Kaiko RF, Grandy RP, Oshlack B, et al. The United States experience with oral controlled-release morphine (MS contin tablets): review of nine dose titration studies and clinical pharmacology of 15-mg, 30-mg, 60-mg, and 100-mg tablet strengths in normal subjects. Cancer 1989;63:Suppl: 2348-54.
69. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-81.
70. Acute Pain Management Guideline Panel. Acute pain management: operative or medical procedures and trauma: clinical practice guideline. No. 1. Rockville, Md.: Agency for Health Care Policy and Research, 1992. (AHCPR publication no. 92-0032.)
71. Levy MH. Constipation and diarrhea in cancer patients. Cancer Bull 1991;43:412-22.
72. Bruera E, Suarez-Almazor M, Velasco A, Bertolino M, MacDonald SM, Hanson J. The assessment of constipation in terminal cancer patients admitted to a palliative care unit: a retrospective review. J Pain Symptom Manage 1994;9:515-9.
73. Bruera E, Macmillan K, Hanson J, MacDonald RN. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 1989;39:13-6.
74. Vainio A, Ollila J, Matikainen E, Rosenberg P, Kalso E. Driving ability in cancer patients receiving long-term morphine analgesia. Lancet 1995; 346:667-70.
75. Sawynok J, Yaksh TL. Caffeine as an analgesic adjuvant: a review of pharmacology and mechanisms of action. Pharmacol Rev 1993;45:43-85.
76. Bruera E, Brenneis C, Paterson AH, MacDonald RN. Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. J Pain Symptom Manage 1989;4:3-6.
77. Eisele JH Jr, Grigsby EJ, Dea G. Clonazepam treatment of myoclonic contractions associated with high-dose opioids: case report. Pain 1992;49: 231-2.
78. Watanabe S, Bruera E. Corticosteroids as adjuvant analgesics. J Pain Symptom Manage 1994;9:442-5.
79. Watson CPN. Antidepressant drugs as adjuvant analgesics. J Pain Symptom Manage 1994;9:392-405.
80. Potter WZ, Rudorfer MV, Manji H. The pharmacologic treatment of depression. N Engl J Med 1991;325:633-42.
81. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250-6.
82. McQuay HJ. Pharmacological treatment of neuralgic and neuropathic pain. In: Hanks GW, ed. Cancer survey series: advances & prospects in clinical, epidemiological and laboratory oncology. Vol. 7. No. 1. Pain and cancer, Oxford, England: Oxford University Press, 1988:141-59.
83. Reddy S, Patt RB. The benzodiazepines as adjuvant analgesics. J Pain Symptom Manage 1994;9:510-4.
84. Mellick GA, Mellicy LB, Mellick LB. Gabapentin in the management of reflex sympathetic dystrophy. J Pain Symptom Manage 1995;10:265-6.
85. Dejgard A, Petersen P, Kastrup J, Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 1988;1:9-11.
86. Tanelian DL, Victory RA. Sodium channel-blocking agents: their use in neuropathic pain conditions. Pain Forum 1995;4:75-80.
87. Fromm GH. Baclofen as an adjuvant analgesic. J Pain Symptom Manage 1994;9:500-9.
88. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488-93.
89. Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer Radiother Oncol 1994;31:33-40.
90. Mercadante S. The role of octreotide in palliative care. J Pain Symptom Manage 1994;9:406-11.
91. Glover D, Lipton A, Keller A, et al. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer: a dose-seeking study. Cancer 1994;74:2949-55.
92. Purohit OP, Anthony C, Radstone CR, Owen J, Coleman RE. High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 1994; 70:554-8.
93. Robinson RG, Preston DF, Schiefelbein M, Baxter KG. Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 1995; 274:420-4.
94. Jaeger H, Maier C. Calcitonin in phantom limb pain: a double-blind study. Pain 1992;48:21-7.
95. Szanto J, Ady N, Jozsef S. Pain killing with calcitonin nasal spray in patients with malignant tumors. Oncology 1992;49:180-2.
96. Ward SE, Goldberg N, Miller-McCauley V, et al. Patient-related barriers to management of cancer pain. Pain 1993;52:319-24.
97. Von Roenn JH, Cleeland CS, Gonin R, Hatfield AK, Pandya KJ. Physician attitudes and practice in cancer pain management: a survey from the Eastern Cooperative Oncology Group. Ann Intern Med 1993;119:121-6.
98. Davis DA, Thomson MA, Oxman AD, Haynes RB. Changing physician performance: a systematic review of the effect of continuing medical education strategies. JAMA 1995;274:700-5.
99. Ferrell BR, Dean GE, Grant M, Coluzzi P. An institutional commitment to pain management. J Clin Oncol 1995;13:2158-65.
100. American Pain Society Quality of Care Committee. Quality improvement guidelines for the treatment of acute pain and cancer pain. JAMA 1995;274:1874-80.
101. Portenoy RK. Chronic opioid therapy in nonmalignant pain. J Pain Symptom Manage 1990;5:Suppl:S46-S62.